AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15155712
Drug: Combined H1‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined H1‐receptor inhibition and NO synthase inhibition
Trial: 15155712
Drug: H2‐receptor inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2‐receptor inhibition
Trial: 2609672
Drug: Intravenous Doxepin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Doxepin treatment
Trial: 2609672
Drug: Oral Doxepin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Doxepin treatment
Trial: 26483357
Drug: Dronabinol 10
RxNorm normalized name: dronabinol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol 10 mg
Trial: 23684127
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning methodology using pre-treatment EEG data for predicting response to SSRI treatment
Trial: 21275593
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment coverage (80%-90%)
Trial: 21275593
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment coverage (over 90%)
Trial: 21275593
Drug: Annual treatment
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual treatment for 3 years
Trial: 21275593
Drug: Graduation rule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graduation rule (halt treatment based on absence of follicular trachoma or infection)
Trial: 19783552
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine (1000 mg/m²) and split-dose cisplatin (40 mg/m²) administered on days 1 and 8 at 3-week intervals for four cycles.
Trial: 19783552
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine and split-dose cisplatin
Trial: 16571153
Drug: Tomatoes, tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomatoes, tomato juice, tomato purée (12.5 mg lycopene/d for 4 weeks)
Trial: 24178584
Drug: Classroom-centered (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom-centered (CC) intervention
Trial: 8739513
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (300 micrograms and 600 micrograms per day by nasal spray for 6 months)
Trial: 2017313
Drug: defibrotide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days)
Trial: 29077924
Drug: Perioperative Behavioral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative Behavioral Therapy (BPMT)
Trial: 17437654
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg kg‐1
Trial: 9512946
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (HES) 200 ml/l of ascites removed, n = 27
Trial: 7527326
Drug: Quinapril 10
RxNorm normalized name: quinapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 10 to 40 mg/day
Trial: 30691753
Drug: Combined exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined exercise therapy (closed kinetic chain exercises and proprioception exercises)
Trial: 26761968
Drug: Thiotriazoline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotriazoline (600 mg/d)
Trial: 26761968
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg/d)
Trial: 17592240
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (IVT) 4 mg
Trial: 12900738
Drug: Metoprolol (MET),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (MET), 50 mg
Trial: 12900738
Drug: Amlodipine (AML),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (AML), 5 mg
Trial: 10847214
Drug: Computerized self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized self‐administered interview
Trial: 8415401
Drug: Buffered solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered solution of didanosine
Trial: 8415401
Drug: Chewable tablet
RxNorm normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablet and antacid suspension
Trial: 8415401
Drug: Buffered solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered solution of didanosine in humans
Trial: 22290044
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) injections
Trial: 22457293
Drug: 23vP (23-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23vP (23-valent unconjugated pneumococcal polysaccharide vaccine)
Trial: 15910869
Drug: Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg
Trial: 16292115
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management plus treatment as usual
Trial: 25024314
Drug: ABT-288 3
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-288 3 mg
Trial: 20140523
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy with recombinant human arylsulfatase B (rhASB) at 1 mg/kg weekly for up to 240 weeks
Trial: 18762755
Drug: Neuroprotective agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroprotective agents
Trial: 8858268
Drug: Cilazapril 0.5
RxNorm normalized name: cilazapril 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 0.5 mg daily
Trial: 1298871
Drug: 5-hydroxytryptophan (OH-TRY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (OH-TRY) 500 mg
Trial: 720003
Drug: Propranolol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (single dose)
Trial: 6370283
Drug: Metoprolol (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (chronic treatment)
Trial: 25139469
Drug: Correction methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correction methods applied to Women's Health Initiative hormone therapy trials
Trial: 21728788
Drug: Weighted balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted balloon catheter with 1000 mL fluid bag
Trial: 19097106
Drug: 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg contrast agent
Trial: 19097106
Drug: 0.2 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mmol/kg contrast agent
Trial: 10720857
Drug: Alfuzosin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 2.5 mg thrice daily
Trial: 1422291
Drug: Xylocaine spray
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylocaine spray with frigen, two applications (20 mg lidocaine)
Trial: 1422291
Drug: Xylestesin spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylestesin spray with frigen, two applications (14 mg lidocaine)
Trial: 1422291
Drug: Xylestesin spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylestesin spray with frigen, three applications (21 mg lidocaine)
Trial: 1422291
Drug: Xylestesin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylestesin pump spray without frigen, two applications (14 mg lidocaine)
Trial: 1392679
Drug: no topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no topical anesthesia
Trial: 30973547
Drug: +NENS (nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +NENS (nutrition education and nutrition supplements)
Trial: 30973547
Drug: +NS (nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +NS (nutrition supplements)
Trial: 30973547
Drug: +NS (nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +NS (nutrition supplements) and +NENS (nutrition education and nutrition supplements)
Trial: 26687921
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both (CI)
Trial: 23135690
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 10 mL/kg‐1 at a rate of 10 breaths/minute (Group 10)
Trial: 23135690
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 5 mL/kg‐1 with 5 cmH2O PEEP at a rate of 20 breaths/minute (Group 5)
Trial: 2221490
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g vitamin C
Trial: 16368837
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position during initiation of small-dose combined spinal-epidural anesthesia (CSE)
Trial: 16368837
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position during initiation of small-dose combined spinal-epidural anesthesia (CSE)
Trial: 11004326
Drug: Continuous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous ceftazidime infusion
Trial: 1451928
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation
Trial: 3711028
Drug: Haloperidol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1, 2, and 5 mg/day for 2 weeks)
Trial: 29763659
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg
Trial: 19671948
Drug: Positive anti-TPO
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive anti-TPO antibodies
Trial: 20057257
Drug: Community-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based medication reconciliation (CMR) system, involving a clinical pharmacist visiting patients' homes within 72 hours of hospital discharge.
Trial: 20057257
Drug: Community-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based medication reconciliation (CMR) system
Trial: 15928790
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation and work therapy
Trial: 11764012
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (placebo)
Trial: 12095665
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral cocaine HCl
Trial: 12095665
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of oral cocaine HCl
Trial: 29901753
Drug: 1000 µg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 µg folic acid daily (as part of a multivitamin) throughout pregnancy and lactation until 8 weeks postpartum
Trial: 10513865
Drug: Ondansetron (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (2.0 mL = 4.0 mg)
Trial: 7725371
Drug: Systematic approach
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic approach to individualizing phenytoin dose based on one-point, steady-state plasma concentration
Trial: 6156412
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g i.v. gammaglobulin (Intraglobin)
Trial: 12582353
Drug: Cancellous cores
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancellous cores (CC) harvested through a 0.5- to 1.0-cm incision with a motor-driven trephine
Trial: 1431009
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg daily in divided doses (increased at week 3 if necessary)
Trial: 7652032
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg/kg
Trial: 23121473
Drug: Vildagliptin +
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin + metformin
Trial: 18513646
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BMC treatment)
Trial: 15742825
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum 0 mg (placebo)
Trial: 15742825
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum 100 mg (low dose)
Trial: 15742825
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum 300 mg (high dose)
Trial: 12095806
Drug: Trimethoprim (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (160 mg)/sulfamethoxazole (800 mg) every 3 days (61 patients)
Trial: 9827404
Drug: Lower than
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower than recommended heparin dosage
Trial: 2684551
Drug: Slow-release oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oral ketotifen
Trial: 27824434
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 266 mg/20 mL (admixed with standard bupivacaine 0.5% 20 mL)
Trial: 27824434
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% 20 mL
Trial: 22683226
Drug: Controlled-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbamazepine 200 mg/day up-titrated to 600 mg/day
Trial: 11865962
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular varicella zoster immune globulin (VZIG)
Trial: 10526698
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (lipophilic agents such as timolol, metoprolol, propranolol, bisoprolol, and carvedilol)
Trial: 7839425
Drug: Double-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug therapy (azathioprine and prednisolone)
Trial: 1610863
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (cyclosporine, azathioprine, and prednisolone)
Trial: 7839425
Drug: Triple-drug to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug to double-drug therapy conversion
Trial: 2495049
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 mg three times daily for the first month, then 40 mg three times daily thereafter)
Trial: 2568785
Drug: Iohexol 300
RxNorm normalized name: IOHEXOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol 300 mg I/ml
Trial: 514499
Drug: Conray meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conray meglumine 282 mg I/ml
Trial: 7043304
Drug: Amipaque 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amipaque 300 mg I/ml
Trial: 30600733
Drug: Histopathology diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histopathology diagnosis of collagenous colitis (CC)
Trial: 12953084
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium clodronate (2080 mg/day)
Trial: 30472902
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release CLM tablets
Trial: 23786783
Drug: Methotrexate 20
RxNorm normalized name: METHOTREXATE 20MG/0.8ML SOLN INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 20 mg subcutaneously once weekly
Trial: 20067113
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no medication before resection)
Trial: 10376168
Drug: Diclofenac-potassium 50
RxNorm normalized name: Diclofenac Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac-potassium 50 mg
Trial: 10376168
Drug: Diclofenac-potassium 100
RxNorm normalized name: Diclofenac Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac-potassium 100 mg
Trial: 6474360
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (continuous infusion after premedication)
Trial: 6474360
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (for high-risk patients)
Trial: 19379098
Drug: 0.5% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% sodium hypochlorite solution
Trial: 30017164
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate solution
Trial: 30017164
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium bicarbonate solution
Trial: 18959455
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy sessions (pre and postoperative)
Trial: 12840089
Drug: Nebulized epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized epinephrine (1 percent, 4 ml doses)
Trial: 12840089
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline, 4 ml doses)
Trial: 11197923
Drug: Individual psychosocial
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual psychosocial treatment
Trial: 6396120
Drug: Bifonazole cream
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole cream applied once or twice daily
Trial: 30764582
Drug: Hibiscus sabdariffa
RxNorm normalized name: HIBISCUS SABDARIFFA CALYX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabdariffa calyces (HSC) extract (250 mL)
Trial: 22420698
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no-treatment)
Trial: 20830731
Drug: GAD-alum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (20 μg, two injections)
Trial: 12698306
Drug: Diosmin 500
RxNorm normalized name: diosmin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin 500 mg once daily for 9 days before metronidazole administration
Trial: 12698306
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg (two tablets) administered after diosmin pretreatment
Trial: 12698306
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg (two tablets) administered alone (no diosmin pretreatment)
Trial: 27681702
Drug: Rivastigmine capsule
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsule (1.5, 3, 4.5, and 6 mg/12 h)
Trial: 23445266
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL physiologic saline)
Trial: 21465735
Drug: 30-minute IV
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute IV infusion of zoledronic acid 4 mg (in 250 mL)
Trial: 20005647
Drug: Dydrogesterone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (40 mg stat followed by 10 mg twice daily)
Trial: 15343587
Drug: Insulin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.05 units/kg)
Trial: 10942153
Drug: Dipyridamole, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole, 200 mg p.o., 3‐4 h before surgery
Trial: 2498074
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) suspension administered by nasogastric feeding tube during continuous enteral feeding infusion
Trial: 30408325
Drug: Rats administered
RxNorm normalized name: rat skin extract
DrugBank: Rattus norvegicus skin (DB10608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rats administered 100 µmol kg-1 SFN
Trial: 18454661
Drug: Locally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally delivered doxycycline gel at baseline and 1 and 2 years as an adjunct to mechanical debridement
Trial: 8936563
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole orally once daily for 10 days
Trial: 8936563
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily for 10 days
Trial: 8464611
Drug: Mucin-containing lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucin-containing lozenge